Phase I study of single-dose BMY-28100, a new oral cephalosporin.

The objective of this Phase I study was to evaluate the safety, tolerance, and pharmacokinetics of BMY-28100 in 36 male subjects after the administration of single oral doses of 250, 500, and 1,000 mg. The subjects were divided into groups of 12 per dose group. All subjects completed the study, and...

Deskribapen osoa

Xehetasun bibliografikoak

Argitaratua izan da:	Antimicrob Agents Chemother
Egile Nagusiak:	Barbhaiya, R H, Gleason, C R, Shyu, W C, Wilber, R B, Martin, R R, Pittman, K A
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology (ASM) 1990
Gaiak:	Research Article
Sarrera elektronikoa:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC171556/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2327766/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.34.2.202
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!